XML 31 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 18 Months Ended
Jun. 30, 2015
May 31, 2014
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2013
Dec. 31, 2016
Share-based Compensation                
Expected term         6 years 3 months 6 years 3 months    
Level 1                
Fair Value Measurements                
Carrying value of cash held in money market fund     $ 117,100,000   $ 117,100,000     $ 38,000,000
Level 2                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     0   0     0
Level 3                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     0   $ 0     $ 0
Maximum                
Share-based Compensation                
Expiration period         10 years      
Pfizer | License Agreement                
Revenue Recognition                
Milestone revenue     $ 0 $ 0 $ 0 $ 0    
Pfizer | License Agreement | Up-Front Payment Arrangement                
Revenue Recognition                
Upfront payment revenue recognized             $ 22,500,000  
Recognition period of up-front payment             1 year 6 months  
Achievement Of Specified Development Milestone | Pfizer | License Agreement                
Revenue Recognition                
Milestone revenue $ 20,000,000 $ 15,000,000